Evidence map›Paper›PMID 26419926›Full record

ArticleBMC infectious diseases2015

Review of a two-year methicillin-resistant Staphylococcus aureus screening program and cost-effectiveness analysis in Singapore.

Mar-Kyaw Win, Tarek Abdellatif Aly Soliman, Linda Kay Lee, Chia Siong Wong, Angela Chow, Brenda Ang, Carrasco L Roman, Yee-Sin Leo

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Mar-Kyaw WinInstitute of Infectious Diseases and Epidemiology, Tan Tock Seng Hospital, Singapore, Singapore. mar_kyaw_win@ttsh.com.sg.
Tarek Abdellatif Aly SolimanSaw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore. Tarek.Soliman@niwa.co.nz.
Linda Kay LeeInstitute of Infectious Diseases and Epidemiology, Tan Tock Seng Hospital, Singapore, Singapore. linda_k_lee@ttsh.com.sg.
Chia Siong WongInstitute of Infectious Diseases and Epidemiology, Tan Tock Seng Hospital, Singapore, Singapore. chia_siong_wong@ttsh.com.sg.
Angela ChowInstitute of Infectious Diseases and Epidemiology, Tan Tock Seng Hospital, Singapore, Singapore. angela_chow@ttsh.com.sg.
Brenda AngInstitute of Infectious Diseases and Epidemiology, Tan Tock Seng Hospital, Singapore, Singapore. Brenda_ang@ttsh.com.sg.
Carrasco L RomanDepartment of Biological Sciences, National University of Singapore, Singapore, Singapore. dbsctlr@nus.edu.sg.
Yee-Sin LeoInstitute of Infectious Diseases and Epidemiology, Tan Tock Seng Hospital, Singapore, Singapore. yee_sin_leo@ttsh.com.sg.
Tan Tock Seng Hospital · SGNational University of Singapore · SGNational University Health System · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMethicillin-resistant Staphylococcus aureus (MRSA) poses an increasingly large disease and economic burden worldwide. The effectiveness of screening programs in the tropics is poorly understood. The aims of this study are: (i) to analyze the factors affecting MRSA colonization at admission and acquisition during hospitalization and (ii) to evaluate the cost-effectiveness of a screening program which aims to control MRSA incidence during hospitalization.

methodsWe conducted a retrospective case-control study of patients admitted to the Communicable Disease Centre (CDC) in Singapore between Jan 2009 and Dec 2010 when there was an ongoing selective screening and isolation program. Risk factors contributing to MRSA colonization on admission and acquisition during hospital stay were evaluated using a logistic regression model. In addition, a cost-effectiveness analysis was conducted to determine the cost per disability-adjusted life year (DALY) averted due to implementing the screening and isolation program.

resultsThe average prevalence rate of screened patients at admission and the average acquisition rate at discharge during the study period were 12.1 and 4.8 % respectively. Logistic regression models showed that older age (adjusted odds ratio (OR) 1.03, 95 % CI 1.02-1.04, p < 0.001) and dermatological conditions (adjusted OR 1.49, 95 % CI 1.11-1.20, p = 0.008) were independently associated with an increased risk of MRSA colonization at admission. Age (adjusted OR 1.02, 95 % CI 1.01-1.03, p = 0.002) and length of stay in hospital (adjusted OR 1.04, 95 % CI 1.03-1.06, p < 0.001) were independent factors associated with MRSA acquisition during hospitalization. The screening and isolation program reduced the acquisition rate by 1.6 % and was found to be cost saving. For the whole study period, the program cost US$129,916, while it offset hospitalization costs of US$103,869 and loss of productivity costs of US$50,453 with -400 $/DALY averted. DISCUSSION: This study is the first to our knowledge that evaluates the cost-effectiveness of screening and isolation of MRSA patients in a tropical country. Another unique feature of the analysis is the evaluation of acquisition rates among specific types of patients (dermatological, HIV and infectious disease patients)and the comparison of the cost-effectiveness of screening and isolation between them.

conclusionsOverall our results indicate high MRSA prevalence that can be cost effectively reduced by selective screening and isolation programs in Singapore.

Indexed as

AdolescentAdultAgedAged, 80 and overAge FactorsCarrier StateCase-Control StudiesCost-Benefit AnalysisCross InfectionFemaleHospitalizationHospitalsHumansIncidenceLength of StayLogistic Models

Identifiers

PMID26419926
PMCPMC4587866
OpenAlexW2110682447

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.